Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)

Familial Partial Lipodystrophy Clinical Trial

Official title:
An Open-label Phase 2 Study of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Subjects With Familial Partial Lipodystrophy

Status Completed

Clinical Trial Summary

This is a single-center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3-LRx for reduction of fasting triglycerides in participants with familial partial lipodystrophy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03514420
Study type	Interventional
Source	Akcea Therapeutics
Contact
Status	Completed
Phase	Phase 2
Start date	June 15, 2018
Completion date	August 21, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02654977` - CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy	Phase 2
Completed	`NCT03508687` - Study of Gemcabene in Adults With FPLD	Phase 1/Phase 2
Completed	`NCT02430077` - Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients	Phase 2
Completed	`NCT05088460` - A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)	Phase 2
Terminated	`NCT02527343` - The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy	Phase 2/Phase 3
Available	`NCT02404896` - Expanded Access Metreleptin Study